Almirall (OTCMKTS:LBTSF – Get Free Report) is expected to be posting its resultson Monday, November 9th. Analysts expect Almirall to post earnings of $0.1498 per share and revenue of $354.30 million for the quarter.
Almirall Stock Performance
LBTSF opened at $15.35 on Monday. Almirall has a 1-year low of $13.36 and a 1-year high of $15.47. The stock’s 50 day simple moving average is $15.35 and its 200 day simple moving average is $15.36.
Almirall Company Profile
Almirall, SA is a Spain-based global pharmaceutical company focused on medical dermatology. The company develops, manufactures and commercializes prescription medicines and other treatments for skin conditions, with research activities centered on areas such as psoriasis, atopic dermatitis, acne, actinic keratosis and other inflammatory or dermatological diseases.
Its portfolio includes therapies such as Ilumetri (tildrakizumab) for plaque psoriasis and Klisyri (tirbanibulin) for actinic keratosis, along with treatments for additional dermatological conditions.
See Also
- Five stocks we like better than Almirall
- Royal Caribbean Buys the Beach as Norwegian Fixes the Ship
- SK hynix Says Memory Demand Beats Supply Through 2030—What It Means for Micron and SanDisk
- STMicroelectronics Could Reach New Highs—Here’s What Needs to Happen
- Marvell Eyes a Swing for the AI Networking Fences as Markets Weigh Lumentum Price Tag
Receive News & Ratings for Almirall Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Almirall and related companies with MarketBeat.com's FREE daily email newsletter.
